| Nov 17 |
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
|
| Nov 17 |
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 15 |
HOOKIPA Pharma GAAP EPS of -$1.10, revenue of $4.7M
|
| Nov 14 |
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
|
| Nov 11 |
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
|
| Oct 31 |
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
|
| Oct 30 |
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
|
| Sep 24 |
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
|
| Sep 2 |
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
|
| Aug 30 |
HOOKIPA Pharma Announces Board of Directors Changes
|
